Clinical trial · Interventional
Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma
A Phase I Pilot Study of Tumor Cell - B Lymphoblastoid Cell Line Vaccination in Pediatric Subjects With Relapsed Ewing's Sarcoma and Neuroblastoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Vaccines made from a person's tumor cells and white blood cells may make the body build an effective immune response to kill tumor cells. Interleukin-2 (IL-2) may stimulate the white blood cells to kill tumor cells. Biological therapies, such as cellular adoptive immunotherapy, stimulate the immune system and stop tumor cells from growing. Giving vaccine therapy with IL-2 may be a more effective treatment for Ewing's sarcoma or neuroblastoma. PURPOSE: This phase I trial is studying the side effects of vaccine therapy when given with IL-2 in treating young patients with relapsed or refractory Ewing's sarcoma or neuroblastoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroblastoma | Neuroblastoma | ONTOLOGY_EXACT | 0.90 |
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| aldesleukin | Biological | Aldesleukin | ALIAS |
| autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine | Biological | — | UNRESOLVED |
| therapeutic autologous lymphocytes | Biological | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Year
- Maximum age
- 30 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of Ewing's sarcoma OR neuroblastoma * Relapsed or refractory disease * Epstein-Barr virus positive PATIENT CHARACTERISTICS: Age * 1 to 30 Performance status * Lansky 70-100% OR * ECOG 0-2 Life expectancy * At least 8 weeks Hepatic * Bilirubin \< 2.0 mg/dL * AST and ALT \< 2.5 times normal (in the absence of liver metastases) * Patients without evidence of an obvious relationship between AST/ALT and disease activity are not eligible * Hepatitis B antigen and core antibody negative * Hepatitis C antibody negative Renal * Creatinine clearance \> 50 mL/min Immunologic * HIV 1 and 2 negative * HTLV 1 and 2 negative Other * Not pregnant * Negative pregnancy test * Fertile patients must use effective contraception * No other moribund condition PRIOR CONCURRENT THERAPY: Biologic therapy * At least 3 months since prior autologous stem cell transplantation Chemotherapy * Not specified Endocrine therapy * Not specified Radiotherapy * Not specified Surgery * Not specified
References
Publications (0)
Data not yet available